GW Henssler & Associates Ltd. grew its position in Sanofi (NASDAQ:SNY) by 2.9% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,805 shares of the company’s stock after acquiring an additional 4,305 shares during the period. GW Henssler & Associates Ltd.’s holdings in Sanofi were worth $7,508,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Cardinal Capital Management Inc. purchased a new stake in Sanofi during the first quarter worth about $25,000. Reby Advisors LLC purchased a new stake in Sanofi during the fourth quarter worth about $35,000. Arkadios Wealth Advisors purchased a new stake in Sanofi during the fourth quarter worth about $36,000. Charter Oak Capital Management LLC purchased a new stake in Sanofi during the fourth quarter worth about $40,000. Finally, JJJ Advisors Inc. raised its position in Sanofi by 193.8% during the fourth quarter. JJJ Advisors Inc. now owns 852 shares of the company’s stock worth $41,000 after acquiring an additional 562 shares during the last quarter. 6.93% of the stock is currently owned by institutional investors and hedge funds.
SNY stock traded down $0.32 on Tuesday, hitting $50.57. 9,863 shares of the company were exchanged, compared to its average volume of 2,294,616. Sanofi has a twelve month low of $44.76 and a twelve month high of $55.00. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.85 and a quick ratio of 1.38. The business’s fifty day moving average is $50.43 and its two-hundred day moving average is $48.86. The stock has a market capitalization of $127.33 billion, a price-to-earnings ratio of 21.74, a price-to-earnings-growth ratio of 1.90 and a beta of 0.55.
The business also recently declared an annual dividend, which will be paid on Wednesday, May 26th. Investors of record on Tuesday, May 4th will be given a dividend of $1.9061 per share. This is a positive change from Sanofi’s previous annual dividend of $1.21. The ex-dividend date is Monday, May 3rd. This represents a yield of 3.2%. Sanofi’s dividend payout ratio is 35.24%.
SNY has been the subject of a number of research reports. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of Sanofi in a research report on Friday. UBS Group restated a “buy” rating on shares of Sanofi in a research report on Tuesday, January 19th. Barclays restated an “equal weight” rating on shares of Sanofi in a research report on Thursday, April 29th. Finally, Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a research report on Wednesday, February 10th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $53.00.
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.